As an essential component of the global medical device sector, in vitro diagnostics (IVDs) are directly linked to the accuracy and reliability of medical diagnoses through their product quality and safety. With the deepening development of international trade, the implementation standards of IVD products have become a key focus for regulatory agencies worldwide and a crucial barrier for companies to participate in international competition.
Currently, international IVD products primarily adhere to regional regulations and standards. The EU, centered around the In Vitro Diagnostic Medical Device Regulation (IVDR 2017/746), imposes strict requirements on risk classification, technical documentation, and clinical evaluation. The US Food and Drug Administration (FDA) emphasizes analytical performance and clinical effectiveness through its in vitro diagnostic reagent approval process. In recent years, China has also accelerated the alignment of its standards with international standards. The implementation of regulations such as the "In Vitro Diagnostic Reagent Registration and Filing Management Measures" has further raised the industry's entry barriers.
For foreign trade companies, a thorough understanding of the implementation standards of target markets is crucial. On the one hand, products that meet international standards can more easily gain market access, reducing trade barriers. On the other hand, high-standard products can earn the trust of international customers and enhance brand competitiveness. For example, after the implementation of the EU IVDR, companies will need to strengthen their quality management systems to ensure compliance throughout the entire process, from R&D to production. The US market, on the other hand, prioritizes product innovation and data support, requiring companies to plan clinical trials and registration pathways in advance.
In the future, as in vitro diagnostic technology continues to advance globally, implementation standards will become more stringent and converge. Foreign trade companies should closely monitor regulatory developments in various countries, actively participate in the development of international standards, and promote higher-quality development of in vitro diagnostic products in the international market through technological upgrades and optimized quality management.